At 9.6% CAGR, the North America Antimicrobial Surgical Suture Market is Projected to be Worth US$ 329.52 Million by 2031, Says Business Market Insights

According to Business Market Insights' research, the North America antimicrobial surgical suture market was valued at US$ 159.64 in 2023 and is expected to reach US$ 329.52 million by 2031, registering a CAGR of 9.6% from 2024–2031. Strategic initiatives by key market players and increasing cases of chronic wounds and surgeries are among the critical factors attributed to the North America antimicrobial surgical suture market expansion.

Sutures are frequently used to close post-operative wounds and to treat deep wounds caused during road and occupational accidents, orthopedic injuries, and sports injuries, owing to their ability to stimulate natural healing. Suturing has significantly transformed the wound closure process by accelerating it. However, wound care management is a complex process and surgical site infections are the most common medical infections observed among the large population. As per the Centers for Disease Control and Prevention (CDC) 2024 report, surgical site infections account for 20% of all hospital-acquired infections, and they are associated with 2–11-fold increase in mortality in 75% of death cases related to surgical site complications. Additionally, surgical site infections contribute significantly to postoperative mortality and morbidity rates. As per the National Library medicine 2024 report, surgical site infections are responsible for more than 2 million nosocomial infections in the US. According to WHO, in low- and middle-income countries, 11% of patients who undergo surgery develop an infection during the process. To fight against surgical site infections, scientists have developed nanosilver-impregnated silk sutures. Nanosilver possesses antimicrobial properties, and its optical and structural characteristics make it an appealing candidate for biomedical applications. The increasing number of cases of surgical site infections is driving the need for sutures that have antimicrobial properties. In July 2022, Dolphin Sutures launched its antibacterial range of antibacterial sutures containing Triclosan coating, which is a known broad-spectrum antibacterial and antifungal agent. Therefore, increasing prevalence of surgical site infections are expected to create demand for antimicrobial surgical sutures and drive the growth of antimicrobial surgical sutures market.

On the contrary, non-invasive alternatives to stitches hamper the growth of North America antimicrobial surgical suture market.

Based on type, the North America antimicrobial surgical suture market is bifurcated into triclosan antimicrobial suture and chlorhexidine antimicrobial suture. The triclosan antimicrobial suture segment held 65.9% share of the North America antimicrobial surgical suture market in 2023, amassing US$ 105.21 million. It is projected to garner US$ 217.62 million by 2031 to expand at 9.6% CAGR during 2024–2031.

By raw materials, the North America antimicrobial surgical suture market is segmented into polyglactin 910 antimicrobial suture, poliglecaprone 25, and polyglycolic acid. The polyglactin 910 antimicrobial suture segment held 55.2% share of the North America antimicrobial surgical suture market in 2023, amassing US$ 88.07 million. It is projected to garner US$ 182.32 million by 2031 to expand at 9.6% CAGR during 2024–2031.

By application, the North America antimicrobial surgical suture market is segmented into cardiovascular surgery, general surgery, ophthalmic surgery, gynecological surgery, orthopedic surgery, plastic surgery, veterinary surgery, dental surgery, and others. The cardiovascular surgery segment held 33.2% share of the North America antimicrobial surgical suture market in 2023, amassing US$ 52.99 million. It is projected to garner US$ 110.17 million by 2031 to expand at 9.7% CAGR during 2024–2031.

By end user, the North America antimicrobial surgical suture market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals surgery segment held 45.4% share of the North America antimicrobial surgical suture market in 2023, amassing US$ 72.47 million. It is projected to garner US$ 147.73 million by 2031 to expand at 9.4% CAGR during 2024–2031.

Based on country, the North America antimicrobial surgical suture market is segmented into the US, Canada, and Mexico. The US held 84.7% share of North America antimicrobial surgical suture market in 2023, amassing US$ 135.28 million. It is projected to garner US$ 275.81 million by 2031 to expand at 9.4% CAGR during 2024–2031.

Key players operating in the North America antimicrobial surgical suture market are Advanced MedTech Solutions Pvt. Ltd.; Cencora, Inc. (AmerisourceBergen Corporation); Healthium Medtech Limited; Internacional Farmacéutica SA; Johnson & Johnson; Meril Life Sciences Pvt Ltd; TI Medical; and Unilene, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com